IGFBP2 and central nervous system cancer: In gliomas, SMOC1 (Wang J. et al., 2021), S100A6 (Hong et al., 2023), CTSB (Ma et al., 2022), SPP1 (Chen et al., 2019), and IGFBP2 (Moore et al., 2009) serve as a potential therapeutic target in glioma.